26 Jan 2024 --- Lallemand Bio-Ingredients’ recent acquisition of Swiss biotechnology firm Evolva for a reported CHF20 million (∼US$23 million) will enable the company to produce complex molecules from yeast for the first time. Meanwhile, Lallemand will bring improved economies of scale and market accessibility to Evolva and its proprietary precision fermentation technology through its global reach. In this exclusive interview, Lars Asferg, president and general manager at Lallemand Bio-Ingredients, tells Nutrition Insight why the Canadian company targeted Evolva, what future investments to expect and the key focuses this year for his business unit.
